Onabotulinumtoxin A Injections for Patients With Pelvic Floor Dysfunction

Area of Science:

• Urology
• Gynecology
• Pain Management

Background:

• Pelvic floor dysfunction affects a significant portion of patients with chronic pelvic pain, often stemming from myofascial sources.
• Current management includes physical therapy and local anesthetic trigger point injections.
• Onabotulinum toxin A is considered for patients with refractory symptoms or barriers to conventional treatments.

Purpose of the Study:

• To review the literature on onabotulinum toxin A injections for pelvic floor dysfunction.
• To provide a detailed demonstration of the injection technique.

Main Methods:

• A comprehensive pelvic floor examination is performed to identify hypertonicity and tenderness.
• Onabotulinum toxin A (200 units) is reconstituted and injected into the pubococcygeus, iliococcygeus, and obturator internus muscles.
• The procedure utilizes a pudendal nerve kit for precise needle depth (1 cm).

Main Results:

• Onabotulinum toxin A injections may provide relief for up to 3-6 months.
• Pain score reduction is typically observed between 6 and 12 weeks post-injection.
• Potential adverse effects include constipation, urinary incontinence, and urinary retention.

Conclusions:

• Onabotulinum toxin A presents a viable therapeutic option for patients with refractory pelvic floor dysfunction.
• The study demonstrates a safe and reproducible method for performing these injections.